Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2022 16:05 ET | Source: Codexis, Inc.

Codexis Reports Third Quarter 2022 Financial Results

REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial...
November 01, 2022 08:00 ET | Source: Codexis, Inc.

Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment...
October 20, 2022 16:05 ET | Source: Codexis, Inc.

Codexis to Report Third Quarter 2022 Financial Results on November 3

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
October 03, 2022 08:00 ET | Source: Codexis, Inc.

Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment...
October 03, 2022 08:00 ET | Source: Codexis, Inc.

Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment...
September 14, 2022 16:05 ET | Source: Codexis, Inc.

Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field

REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent...
August 04, 2022 16:05 ET | Source: Codexis, Inc.

Codexis Reports Second Quarter 2022 Financial Results

Total Revenue up 51% and Product Revenue up 135% YOY 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) --...
August 02, 2022 16:05 ET | Source: Codexis, Inc.

Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis

REDWOOD CITY, Calif. and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular...
July 18, 2022 16:05 ET | Source: Codexis, Inc.

Codexis Announces CEO Transition Effective August 9, 2022

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY,...
July 14, 2022 16:06 ET | Source: Codexis, Inc.

Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right